Drug List. Drugs listed on the Drug List are selected by the Plan based upon the recom mendations of a committee, which is made up of current and previously practicing Physicians and pharmacists from across the country, some of whom are employed by or affiliated with the Plan. The committee considers drugs reg ulated by the FDA for inclusion on the Drug List. As part of the process, the committee reviews data from clinical studies, published literature and opinions from experts who are not part of the committee. Some of the factors committee members evaluate include each drug's safety, effectiveness, cost and how it compares with drugs currently on the Drug List. The committee considers drugs that are newly approved by the FDA, as well as those that have been on the market for some time. Entire drug classes are also reg ularly reviewed. Changes to this list can be made from time to time. Positive changes, such as adding drugs to the Drug List, occur quarterly after review by our committee. Changes to the Drug List that could have an adverse financial im pact to you (e.g., drug exclusion, drugs moving to a higher payment tier, or drugs requiring step therapy or prior authorization) occur only annually. The Drug List and any modifications will be made available to you. The Plan may offer multiple Drug Lists. By accessing the Plan's website at xxx.xxxxxx.xxx or calling the customer service toll‐free number on your identification card, you will be able to determine the Drug List that applies to you and whether a particular drug is on the Drug List. PRIOR AUTHORIZATION/STEP THERAPY REQUIREMENT Prior Authorization (PA): Your benefit plan requires prior authorization for cer tain drugs. This means that your doctor will need to submit a prior authorization request for coverage of these medications and the request will need to be approved before the medication will be covered under the Plan. You and your Physician will be notified of the prescription drug administrator's determination. If medical ne cessity criteria is not met, coverage will be denied and you will be responsible for the full charge incurred.

Drug List. Prescriptions for drugs included on the emergency first-fill drug list see included Exhibit 1 will be dispensed without prior approval. Updates to the drug list will be provided to the vendor for timely incorporation and a hard copy of the updated list will be provided to the VA for verification. The vendor will have a workable system to facilitate timely VA pharmacy approvals for prescriptions for medications that are not listed on the drug list. Flu and Zostavax vaccinations will be authorized under this Order for Qualified Veterans.

Drug List. Within thirty (30) days after the Agreement Date (defined below), MTS and Customer will prepare a mutually agreeable list of drugs to be dispensed using the OnDemand System (the “Drug List”). The Drug List shall include information and specifications sufficient to permit dispensing through cassettes designed specifically to work with the OnDemand System. If necessary, Customer agrees to supply MTS with drug samples (up to 50/each drug) for calibration purposes. Customer may elect to provide MTS with information regarding Customer’s monthly medication usages and Customer’s filling patterns by day or week to allow optimization of the OnDemand System load balance. Customer may provide updated Drug Lists to MTS from time to time, and MTS shall recalibrate or provide additional cassettes (as necessary) in accordance with applicable terms set forth in Addendum A.

Drug List. ...means a list of all drugs that may be covered under the OUTPATIENT PRESCRIPTION DRUG PROGRAM BENEFITS and related services section of this Certificate. A current list is available on our website at xxxxx://xxx.xxxxxx.xxx/member/prescription-drugplan-information/drug -lists other website. You may also contact a Customer Service Representative at the telephone number shown on the back of your Identification Card for more information.

Related to Drug List

Patent Listings Licensee shall have the right and responsibility to make all filings with Regulatory Authorities in the Territory with respect to the AstraZeneca Patents, including as required or allowed (i) in the United States, in the FDA’s Orange Book and (ii) in the European Union, under the national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 or other international equivalents; provided that Licensee shall consult with AstraZeneca to determine the course of action with respect to such filings.
Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.
Customer List The Administrative Agent shall have received a true and complete customer list for each Borrower and its Domestic Subsidiaries, which list shall state the customer’s name, mailing address and phone number and shall be certified as true and correct in all material respects by a Financial Officer of the Borrower Representative.
Product Recalls The Company is not aware of any pattern or series of claims against the Company or any of its subsidiaries which reasonably could be expected to result in a generalized product recall relating to products sold by the Company or any of its subsidiaries, regardless of whether such product recall is formal, informal, voluntary or involuntary.
Product Recall (a) If a recall is required by applicable Law, or if Buyer or Supplier reasonably determines that a recall is advisable because the goods may create a potential safety hazard, are not in compliance with any applicable code, standard or legal requirement, or contain a defect or non-conformance with the requirements of this Order occurring or likely to occur in multiple goods, which such defects or non-conformances are substantially similar or have substantially similar causes or effects (collectively a “Serial Defect”), the parties shall promptly communicate such facts to each other. At Buyer’s request, Supplier shall promptly develop a corrective action plan satisfactory to Buyer, which shall include all actions required to recall and/or repair the goods and any actions required by applicable Law (“Corrective Action Plan”) for Buyer’s review and approval. At Buyer’s election, Xxxxx may develop the Corrective Action Plan. In no event shall Buyer and Supplier’s failure to agree on the Corrective Action Plan delay the timely notification of a potential safety hazard, non-compliance or Serial Defect to users of the goods, cause either party to be non-compliant with applicable Law or prevent Buyer from taking reasonable actions to prevent injury or damage to persons, equipment or other property. Supplier and Buyer shall cooperate with and assist each other in any corrective actions and/or filings, if applicable.
Product Description The lead products covered by this Settlement Agreement is limited to following Amazon Identification Number (ASIN) B0BBMRLNV9, with the description, "Lesnow 63-37 Tin Lead Rosin Core Solder Wire for Electrical Soldering 0.8mm Soldering Wire Electronics Solder Content Solder Flux 1.8% (0.8mm, 50g)," which was offered for sale by the Settling Entity on xxxxxx.xxx, hereinafter the “Product” or “Products.”
Employee List No later than five (5) Business Days after the Bank Closing Date, the Assuming Institution shall provide the Receiver with a list of all Failed Bank employees the Assuming Institution will not hire. Unless otherwise agreed, the Assuming Institution shall pay all salaries and payroll costs for all Failed Bank employees until the list is provided to the Receiver. The Assuming Institution shall be responsible for all costs and expenses (i.e., salary, benefits, etc.) associated with all other employees not on that list from and after the date of delivery of the list to the Receiver. The Assuming Institution shall offer to the Failed Bank employees it retains employment benefits comparable to those the Assuming Institution, offers its current employees.

Drug List Sample Clauses

Filter & Search

Related Clauses

Parent Clauses

Related to Drug List